Bedaquiline, pretomanid and TBD09

Phase 2

IQVIA HOLDINGS INC. (IQV)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

IQVPhase 2$45.3B

Bedaquiline, pretomanid and TBD09 Phase 2 Est. Readout

Bedaquiline, pretomanid and TBD09• Drug Susceptible Pulmonary Tuberculosis150

Nov 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Drug Susceptible Pulmonary Tuberculosis

View Full Landscape

Drug Information

Target Indication

Drug Susceptible Pulmonary Tuberculosis

Clinical Trial

NCT07525427

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/31/2020

Dovprela (previously Pretomanid FGK)

Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IQV

IQVIA HOLDINGS INC.

Services-Commercial Physical & Biological Research•North America•NASDAQ

Related Pipeline

Olokizumab 64 mg SC q4wPhase 3

Rheumatoid Arthritis

Humira 40 MG in Prefilled SyringePhase 3